LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq: STML) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Stemline shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
On February 2, 2017, Bloomberg announced that a patient in a clinical trial of Stemline’s cancer drug SL-401 died from a severe side effect. This is the third death related to SL-401 toxicity.
When this information was released to the public, the value of Stemline stock fell significantly, causing investors severe harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.